Hypercholesterolemia is one of the most important risk factors for cardiovascular diseases (CVDs). Today, strategies and remedies are available to combat CVDs. Hence, most research today focuses on screening and identifying compounds exhibiting anti-hypercholesterolemic properties. Medicinal mushrooms have been scientifically proven to be safe, efficacious, and novel anti-hypercholesterolemia therapeutic agents of natural sources, so they have received extensive attention from researchers.
Lifeasible provides research services for anti-hypercholesterolemia drug development based on the small molecules or extracts from mushrooms. We evaluated the hypocholesterolemic effects of small molecules or extracts from mushrooms in animals by detecting changes in various cardiovascular disease markers, including triacylglycerol, homocysteine, low-density lipoprotein, high-density lipoprotein, etc. We provide a one-stop preclinical research service for the development of mushrooms as an anti-hypercholesterolemia drug to better develop their potential use in the treatment of human diseases.
Mushroom fruiting bodies or their extracts are considered a new source of compounds with potential hypocholesterolemic activity because they are rich in ergosterol derivatives,β-glucans, and HMG-CoA-red inhibitors. Ergosterol derivatives reduce cholesterol absorption by displacing molecules from dietary mixed micelles formed during intestinal digestion. β-glucans reduce cholesterol absorption by inhibiting micelle formation in the small intestine or interacting with the bile acids, leading to an increase in fecal bile acids excretion and increasing hepatic conversion of cholesterol into bile acids. HMG CoA-Red inhibitors impair endogenous cholesterol synthesis by inhibiting HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase, a key enzyme in cholesterol metabolism).
Fig. 1 Potential hypocholesterolemic mechanisms of edible mushroom. (Riaz S, et al., 2022)
Lifeasible provides research services for the anti-hypercholesterolemia drug development of small molecules or extracts from mushrooms. Our services include but are not limited to the following:
Anti-hypercholesterolemia compounds found in mushrooms include polysaccharides, nicotinic acid, triterpenes, ergosterol, polyphenols potassium, vitamin C, fiber, etc. Our research team will extract and isolate target compounds for you according to your needs, accelerating your experimental process.
We constructed a hypercholesterolemia mouse model to evaluate the hypocholesterolemic effect of mushroom extracts, and the evaluation objects were the biomarkers of cardiovascular disease.
Based on the compounds you provide, we conduct structural optimization, in vitro target activity testing, and functional evaluation to help screen candidate drugs with good drug prospects.
Lifeasible provides one-stop preclinical research services for the development of anti-hypercholesterolemia drugs from mushroom extracts. It is helpful to expand people's understanding of the effects of mushroom compounds on human health. If you are interested in our research services, please contact us for a more detailed description of our services.
Reference
For research use only, not for clinical use.